A randomized, double-blind, placebo-controlled, multi-center study toevaluate the efficacy, safety, tolerability, pharmacokineti

A randomized, double-blind, placebo-controlled, multi-center study toevaluate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of orally administered GLPG3667 once daily for 24 weeks in adult subjects with dermatomyositis

Obert

Codi protocol: GLPG3667-CL-214
Codi EudraCT: _
Grup de recerca: Malalties Sistèmiques
Servei: Medicina Interna
Investigador/a principal: Selva O'Callaghan, Albert
Malaltia: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més
Fase: Fase II